NVAX bounces

Shares of Novavax (NVAX +15.2%) enjoy a modest bounce on average volume as money flow returns to the biotech sector today.

Yesterday, the company reported positive top-line results from its Phase 2 dose confirmation trial for its RSV vaccine. The primary endpoint was safety and immune response as measured by IgG-F antibody levels. The highest immune responses were observed in patients that received one dose of vaccine combined with aluminum phosphate adjuvant. No quantitative data were disclosed.

The company has requested a Type C meeting with the FDA for this summer to discuss the data and hopefully get the agency's go-ahead to proceed to a Phase 3 trial. Any FDA approval is easily two years away.

From other sites
Comments (1)
  • Dr Joseph Haluska
    , contributor
    Comments (499) | Send Message
    I know we want our children's vaccines to be safe, but is there a quant who can calculate the cost of all the morbidity of 2 years of RSV in this country?
    29 Apr 2014, 10:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs